XTL Biopharmaceuticals Nominates Gilai Dolev as External Director
Bitget2026/10/14 20:07- XTL Biopharmaceuticals director Iris Shapira Yalon submitted her resignation on October 12, 2026, citing personal reasons.
- Her departure takes effect upon her successor's appointment or November 20, 2026, whichever comes first.
- The board nominated Gilai Dolev on October 14, 2026, as her replacement external director, subject to shareholder approval.
- Dolev would serve an initial three-year term.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
